Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 35 | ECE2014 | Next issue

16th European Congress of Endocrinology

Symposia

EYES Session - Cold metabolic inflammation in obesity: ignored complication and treatment target?

ea0035s9.1 | EYES Session - Cold metabolic inflammation in obesity: ignored complication and treatment target? | ECE2014

Introducing EYES: European Young Endocrine Scientists

Schulte Dominik M

The ‘European Young Endocrine Scientists’ (EYES) founded in 2011, is a committee under the patronage of the European Society of Endocinology (ESE). The primary goal of this committee is to increase the mutual exchange of ideas and knowledge between young endocrinologists – from basic researchers to clinicians – across Europe in the initial stages of their career. EYES enables young endocrinologists (<35 years) from all ESE member societies to actively c...

ea0035s9.2 | EYES Session - Cold metabolic inflammation in obesity: ignored complication and treatment target? | ECE2014

Fertility: PCOS: metformin

Rachon Dominik

Insulin resistance and its resultant hyperinsulinaemia seem to play a pivotal role in the pathogenesis of polycystic ovary syndrome (PCOS), which apart from its cosmetic and metabolic consequences also lead to fertility problems. Therefore, metformin – a biguanide used as the first line of pharmacotherapy in patients with type 2 diabetes mellitus (T2DM), is often prescribed to women with PCOS in order to decrease the consequences of hyperinsulinaemia and to restore ovulat...

ea0035s9.3 | EYES Session - Cold metabolic inflammation in obesity: ignored complication and treatment target? | ECE2014

The emerging landscape for nanomedicine in atherosclerosis

van der Valk F M

Major clinical events such as myocardial infarction and stroke are caused by atherosclerosis, a lipid-driven chronic inflammatory disease affecting the arterial wall. In recognition of the inflammatory drive in cardiovascular disease (CVD), a major interest has risen to complement current standards for high-risk patients by therapeutically targeting the inflammatory process. Prior to clinical application, therapeutic candidates are required to have a robust anti-inflammatory e...